FDA Clears New AI-Powered MRI System from Fujifilm
The Echelon Synergy MRI system reportedly uses deep learning technology to accelerate image acquisition and enhance image quality.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Echelon Synergy magnetic resonance imaging (MRI) system, which combines artificial intelligence (AI) enhancements for image acquisition and quality with improved radiology workflow efficiencies.
The Echelon Synergy MRI system utilizes proprietary Deep Learning Reconstruction technology to improve the quality of MRI scans and the speed of acquiring the images, according to Fujifilm Healthcare Americas Corporation, the manufacturer of the new 1.5 Tesla MRI system.
One key benefit of the Echelon Synergy MRI system is the AutoExam One Touch, which allows automated workflows for brain and knee MRI exams.
In order to facilitate improved patient comfort, Fujifilm said the Echelon Synergy system offers reduced acoustic noise through SoftSound™ gradient technology as well as a 70 cm-wide bore and 62 cm-wide table that can accommodate patients weighing up to 550 pounds.
“Fujifilm is committed to delivering medical advancements focused on enhancing the patient’s experience while streamlining the workflow for today’s busy imaging providers,” noted Shawn Etheridge, the executive director of modality solutions for Fujifilm Healthcare Americas Corporation.
“Echelon Synergy is designed to facilitate optimal comfort and help alleviate anxiety with its large bore and wide patient table. Alleviating any patient anxiety not only helps to enhance the patient experience, but could also improve a radiologist’s workflow, as the less nervous a patient, the more efficient and quickly the scan will get done.”
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Is MRI Contrast Enhancement Necessary for Long-Term Monitoring of Diffuse Glioma?
March 4th 2025In a comparison of contrast-enhanced T1-weighted (CET1w) MRI (and T2-weighted MRI/FLAIR imaging, researchers found that only three out of 82 cases of glioma progression were solely detected with CET1w MRI.
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
